Asthma – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Pediatric Asthma (US)
Pediatric asthma is treated using two types of pharmacotherapies: rescue therapy for acute symptoms via bronchodilation (e.g., a SABA such as Teva’s ProAir HFA) and maintenance therapy to prevent exacerbations by targeting the underlying pathophysiology (e.g., a LABA / ICS such as GSK’s Advair or an anti-IL-5 agent such as AstraZeneca’s Symbicort). Many pediatric asthma patients receive more than one agent for their condition. Despite the availability of multiple well-established therapies, the pediatric asthma treatment landscape has seen the approval and launch of additional agents in recent years, including novel biologics (e.g., Regeneron / Sanofi’s Dupixent) and generic versions of blockbuster inhaled drugs (e.g., albuterol sulfate and salmeterol / fluticasone propionate). These events have added more treatment options and fueled competition in this market.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed pediatric asthma patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed pediatric asthma patients?
- How have newer biological therapies (e.g., GSK’s Nucala, AstraZeneca’s Fasenra, Dupixent) been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of pediatric asthma patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of pediatric asthma patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Markets covered: United States
Key companies: AstraZeneca, GSK, Regeneron, Sanofi, Teva
Key drugs: Advair, Symbicort, Dulera, Breo, Dupixent, Fasenra, Nucala, Xolair, Ventolin, ProAir, albuterol sulfate, montelukast sodium, Flovent, Qvar, Spiriva
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
SOLUTION ENHANCEMENT
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.
Table of contents
- Asthma - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Pediatric Asthma (US)
- Treatment Algorithms: Claims Data Analysis Pediatric Asthma US June 2023
- Treatment Algorithms CDA Pediatric Asthma 2023 Dashboard
Debismitha Priyanka Barua, M.P.H., Healthcare Research & Data Analyst, Immune and Inflammation. Prior to joining Clarivate, Ms. Barua was an epidemiologist for the Massachusetts Department of Public Health. She holds a master’s degree in epidemiology and biostatistics from Boston University’s School of Public Health and a bachelor’s degree in molecular, cellular, and developmental biology from the University of Kansas.